Samsung Biologics
Samsung Biologics is a global biologics CDMO serving biopharma companies with end-to-end cell-line development, drug-substance manufacturing and aseptic fill-finish.
- Public
Samsung Biologics is a global biologics CDMO serving biopharma companies with end-to-end cell-line development, drug-substance manufacturing and aseptic fill-finish.
samsungbiologics.comCrawled Oct 23, 2026
Biologics development services from Samsung Biologics, including cell line development, IND filing support, CGMP manufacturing, and custom CMC solutions.
Samsung Biologics delivers CGMP biopharma manufacturing services - from drug substance to aseptic fill-finish. Scalable CDMO services for quality and speed.
Discover Samsung Biologics’ integrated GMP quality systems, quality control testing, regulatory affairs support, and cGMP compliance services. Expert biologics CDMO with digital QA/QC platforms.
The decision by any institution on the selected host cell line impacts the quality, cost of goods, and speed of the development process. Through this poster,
Accelerated tech transfer timelines are becoming increasingly desirable to support the development and manufacture of biologics that have the potential to add
Samsung Biologics established its articles of incorporation under the Commercial Act and publishes an annual corporate governance report.
The success or failure of a business is directly dependent on how well its supply chain operations are managed, and this is even more so for the pharmaceutic
Samsung Biologics offers brochures detailing its services and capabilities.
Explore Samsung Biologics’ Events page to find upcoming and previous webinars, conferences, and Newsroom event updates.
Samsung Breaks Ground for Biopharmaceutical PlantToday, the venture - Samsung Biologics - held a groundbreaking ceremony in the free economic zone at the port c
Samsung Biologics provides employee wellness benefits for staff and their families.
Samsung Biologics values its employees career development and provides systematic training opportunities to grow professionally.
Samsung Biologics employs over 100 global experts from 11 countries and has been recognized as a ‘Best Family-Friendly Management’ company.
John Rim, CEO of Samsung Biologics, leads the company’s mission to improve accessibility and quality of biomedicines globally.
Samsung Biologics introduces its key executives and their professional stories.
As the world s largest biomanufacturing site by capacity, Bio Campus I supports a broad spectrum of global pharmaceutical and biotech clients with comprehensive end-to-end CDMO services across diverse modalities and molecule types.
Samsung Biologics provides contract development, manufacturing, and biosafety testing services.
As a leading end-to-end service provider, Samsung Biologics has achieved a great number of milestones over the past decade.
Samsung Biologics offers solutions through its representatives for client inquiries.
Samsung Biologics is a leading global CDMO providing end-to-end biologics development, CGMP manufacturing, and aseptic fill/finish services for biopharma partners worldwide.
Samsung Biologics releases its third-quarter 2026 financial performance as a top contract development and manufacturing organization (CDMO). The company operates within the biopharmaceutical sector, specializing in development and production services for biologics. Financial details highlight its ongoing role in supporting drug manufacturing for pharmaceutical clients.
Oct 2026PR NewswireNews article
Samsung Biologics acquires an 87.88% stake in Polypeptide through a tender offer, aiming to expand its contract development and manufacturing organization (CDMO) capabilities for peptide-based therapies. The deal exceeds the minimum threshold required for completion, with Samsung targeting finalization by November. The move aligns with the company’s growth strategy in the biopharmaceutical sector.
Oct 2026CHOSUNBIZNews article
Samsung Biologics secures a **USD 262 million** manufacturing deal with an unnamed European pharmaceutical firm, extending through **2033**. The agreement underscores strong client demand and supports the company’s expansion as a **contract development and manufacturing organization (CDMO)**. The partnership highlights Samsung Biologics’ role in scaling biologics production for global pharmaceutical partners.
Sep 2026Drug Discovery NewsNews article
Samsung Biologics is acquiring PolyPeptide Group in an all-cash tender offer valued at **$1.81 billion** (SFr1.46bn). The deal marks a significant expansion for the biopharmaceutical contract development and manufacturing organization (CDMO). PolyPeptide specializes in peptide-based therapies and advanced biologics production.
Jul 2026Pharmaceutical TechnologyNews article